Campus to hold viewing of movie based on commencement speaker's life

Student Affairs is hosting a viewing of "Extraordinary Measures," the recent movie release based on the experience of John Crowley, this year's commencement speaker at Penn State Lehigh Valley. The film will be shown at 12:15 p.m. on Thursday, April 29, in the auditorium (room 135) at the campus in Center Valley.

The film, "Extraordinary Measures," inspired by the Crowley family's story, stars Brendan Fraser as John Crowley, Harrison Ford as Robert Stonehill, and Keri Russell as Crowley's wife, Aileen, and opened in theaters nationwide in January. The movie was the first to go into production for CBS Films, and Ford also served as executive producer.

Crowley is currently the president and CEO of Amicus Therapeutics, a 100-person publicly-held biopharmaceutical company working on the development of drugs to treat a range of human genetic diseases. His involvement in the biotech industry spans more than a decade and stems from the 1998 diagnosis of his two youngest children, Megan and Patrick, with Pompe disease, a rare and fatal neuromuscular disorder. Crowley embarked on his journey as an entrepreneur to find a treatment that would save his children's lives, and the lives of thousands of others, parlaying his personal struggles and determination into a series of highly successful biotech business ventures and keynote speeches.

Following their diagnosis in 1998, Megan and Patrick were given just months to live. Frustrated with the pace of Pompe research, and wanting to do whatever he and his family could to change the course of their children’s diagnosis, Crowley quit his job as a marketing director at Bristol-Myers Squibb. He then traveled the world over, competing against time as well as business, medical, and scientific establishments that were slow to move and even slower to accept his hard charging determination. Grasping at one last hope, he helped to co-found a five-person start-up biotech company called Novazyme Pharmaceuticals, focused exclusively on developing a treatment for Pompe. In less than a year, the company went from $1 million in angel financing, to $27 million in venture capital financing and was then acquired for nearly $200 million by Genzyme Corporation. On January 9, 2003, Patrick and Megan began to receive an experimental enzyme therapy developed by Genzyme that has saved their lives. They are now in the 6th and 7th grades, respectively. They continue to fight the battle against Pompe one day at a time.

For more information, please contact Beth Shakespeare at

Media Contacts: 
Last Updated November 18, 2010